Professor, Department of Psychiatry
Professor, Department of Pathology
A major focus of Dr. Pomara’s research has been to elucidate pharmacokinetic and pharmacodynamic factors that may contribute to individual vulnerability to drug induced cognitive and psychomotor toxicity in the elderly. He has shown that certain variants of the APOE and TOMM40 genes increase risk for drug-induced adverse events unrelated to pharmacokinetic factors and likely reflecting pharmacodynamic mechanisms.
Other important contributions include his early reports of increased activity in the HPA axis associated with both aging and AD, as determined by studies of baseline cortisol and dexamethasone response. These results led to the first pilot clinical trial that examined the cognitive effects of the glucocorticoid receptor antagonist, RU486, in AD. Dr. Pomara also provided the first report on an absence of a cortisol response to naltrexone and an elevation in CSF-glutamate in Alzheimer’s patients.
Dr. Pomara additionally presented the first evidence that late life depression, a condition associated with increased risk for Alzheimer’s disease (AD) or prodromal phase, may be accompanied by disturbances in central and peripheral metabolism of amyloid-beta, a peptide implicated in AD. More recently, he has been collaborating with the NYU Cohen Veterans Center to identify biomarkers for PTSD/TBI.
International journal of neuroscience. 2020 Mar 31; 1-5
Biomarkers in neuropsychiatry. 2019 Dec; 1:
Neurodegenerative disease management. 2019 Aug; 9(4):189-191
International journal of geriatric psychiatry. 2019 Mar; 34(3):415-419
Scientific reports. 2019; 9:
International psychogeriatrics. 2018 Dec; 30(12):1883-1888
Journal of Alzheimer's disease reports. 2018 Oct 03; 2(1):165-167